1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Nerve Degeneration in 203 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed the influence of aging on substantia nigra degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 7.67 | Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. ( DeLanney, LE; Forno, LS; Irwin, I; Langston, E; Langston, JW; Ricaurte, GA, 1987) |
| "We demonstrate that Eupatilin alleviates behavioral impairment and dopaminergic neuron loss induced by MPTP through inhibition of neuroinflammation and apoptosis." | 3.96 | Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model. ( Li, J; Qin, L; Wang, C; Xie, J; Zhang, Y, 2020) |
| "This study assessed the influence of aging on substantia nigra degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 3.67 | Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. ( DeLanney, LE; Forno, LS; Irwin, I; Langston, E; Langston, JW; Ricaurte, GA, 1987) |
| "Nonhuman primate models of Parkinson's disease (PD) have been invaluable to our understanding of the human disease and in the advancement of novel therapies for its treatment." | 2.43 | Neural repair strategies for Parkinson's disease: insights from primate models. ( Kordower, JH; O'Malley, J; Soderstrom, K; Steece-Collier, K, 2006) |
| "The development of animal models of Parkinson's disease is of great importance in order to test substitutive or neuroprotective strategies for Parkinson's disease." | 2.42 | Animal models of Parkinson's disease in rodents induced by toxins: an update. ( Breidert, T; Cohen-Salmon, C; Feger, J; Hirsch, EC; Höglinger, G; Launay, JM; Parain, K; Prigent, A; Rousselet, E; Ruberg, M, 2003) |
| "Selegiline treatment increased the number of motoneurons surviving axotomy from 24 to 52%, showing that selegiline can rescue neurons by partially compensating for the loss of target-derived trophic support." | 2.38 | Selegiline can mediate neuronal rescue rather than neuronal protection. ( Tatton, WG, 1993) |
| "Selegiline (L-deprenyl) has been shown to delay the need to initiate levodopa therapy in early PD, and selegiline has also been suggested to increase the survival of PD patients." | 2.38 | Nigral degeneration in Parkinson's disease. ( Rinne, JO, 1993) |
| "Since the original description of Parkinson's disease (PD) more than 170 years ago, there have been major advances in the understanding and treatment of PD." | 2.38 | Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease? ( Poirier, J; Thiffault, C, 1993) |
| "Current stem cell therapies for Parkinson's disease (PD) focus on a neurorestorative approach that aims to repair the CNS during the symptomatic phase." | 1.72 | Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage. ( Boese, AC; Hamblin, MH; Lee, JP; Murad, R; Pereira, MCL; Yin, J, 2022) |
| "A major hallmark of Parkinson's disease (PD) is the degeneration of dopaminergic neurons in the substantia nigra, and the causative mechanism is thought to be the activation of programmed neuronal death." | 1.51 | miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease. ( Chen, HZ; Cheng, Q; Cui, HL; Hu, YB; Huang, WY; Ren, RJ; Wang, G; Wang, H; Zhang, YF, 2019) |
| "Hypercholesterolemia is a known contributor to the pathogenesis of Alzheimer's disease while its role in the occurrence of Parkinson's disease (PD) is only conjecture and far from conclusive." | 1.46 | Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress. ( Borah, A; Choudhury, A; Giri, A; Kumar, S; Paul, R; Sandhir, R, 2017) |
| "Although anti-Parkinson's disease activity of puerarin was reported in both of in vivo and in vitro model, detailed mechanisms are not clarified." | 1.40 | Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice. ( Li, Q; Li, X; Wang, X; Wu, S; Zhu, G, 2014) |
| "3% of the administered dose was taken up by the brain and was slowly eliminated, with a half-life of approximately 3 weeks." | 1.39 | Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice. ( Beck, M; Botham, PA; Breckenridge, CB; Butt, M; Cook, AR; Mathews, JM; Minnema, D; Smith, LL; Sturgess, NC; Tisdel, MO; Travis, KZ; Wolf, JC; Zadory, D, 2013) |
| "Studies on Parkinson's disease patients and dopamine-depleted animals indicate that dopaminergic neurons in the retina degenerate due to the genetic and environmental factors that cause dopaminergic neuron loss in the substantia nigra." | 1.37 | Minor retinal degeneration in Parkinson's disease. ( Huang, YM; Yin, ZQ, 2011) |
| "The clinical stage of Parkinson's disease begins after this period." | 1.37 | Experimental modeling of preclinical and clinical stages of Parkinson's disease. ( Bocharov, EV; Khaindrava, VG; Klodt, PD; Kozina, EA; Kryzhanovsky, GN; Kucheryanu, VG; Kudrin, VS; Nanaev, AK; Narkevich, VB; Raevskii, KS; Ugrumov, MV, 2011) |
| "Posttreatment with benzamide also attenuated MPTP neurotoxicity in mice." | 1.36 | Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. ( Araki, T; Kato, H; Kuroiwa, H; Tsukada, T; Uchida, H; Yokoyama, H, 2010) |
| "Curcumin treatment significantly improved behavioral deficits, and enhanced the survival of tyrosine hydroxylase-positive neurons in the substantia nigra (SN) in the MPTP-induced PD model mice." | 1.36 | Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. ( Chi, ZH; Feng, WY; Nie, YX; Wang, NQ; Wang, ZY; Xin, N; Yu, S; Zheng, W, 2010) |
| ") injection of the neurotoxicant, 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine or 2'-CH(3)-MPTP, to postnatal day 4 (PD4) mice caused acute and transient gliosis in the brain, which can be noninvasively monitored during a course of 8 h immediately after the dosing [Ho, G." | 1.35 | Molecular imaging reveals a correlation between 2'-CH3-MPTP-induced neonatal neurotoxicity and dopaminergic neurodegeneration in adult transgenic mice. ( Ho, G; Kng, YL; Kumar, S; Zhang, C; Zhuo, L, 2008) |
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| "Although the pathogenesis of Parkinson's disease (PD) remains unknown, it appears that microglial activation is associated with enhanced neurodegeneration in animal models of PD as well as in PD patients." | 1.33 | Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. ( Hong, JS; Kovacs, M; Liu, J; Ma, T; McLaughlin, P; Zhang, J; Zhang, W; Zhou, Y, 2006) |
| "Parkinson's disease is associated with a progressive loss of substantia nigra pars compacta dopaminergic neurons." | 1.33 | Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. ( Garris, BL; Garris, DR; Lau, YS; Novikova, L, 2006) |
| "Current gene therapy models for Parkinson's disease (PD) have adapted two treatment strategies." | 1.33 | Doxycycline-regulated co-expression of GDNF and TH in PC12 cells. ( Li, KR; Niu, DB; Wang, JJ; Wang, K; Wang, XM; Xue, B; Zhang, T, 2006) |
| " In addition the home cage behaviour of mice administered with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) using an acute dosing regimen was also investigated." | 1.33 | Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. ( Billinton, A; Brown, M; Chapman, H; Quinn, LP; Stean, TO; Upton, N; Vidgeon-Hart, M; Virley, DJ, 2006) |
| "Pre-treatment with captopril induced a significant reduction in the MPTP-induced loss of dopaminergic neurons in the substantia nigra and a significant reduction in the loss of dopaminergic terminals in the striatum." | 1.33 | Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. ( Guerra, MJ; Labandeira-Garcia, JL; Mendez-Alvarez, E; Muñoz, A; Rey, P; Soto-Otero, R, 2006) |
| "Early-onset torsion dystonias are caused by a mutation in TorsinA, a protein widely expressed in the nervous system." | 1.32 | TorsinA, the gene linked to early-onset dystonia, is upregulated by the dopaminergic toxin MPTP in mice. ( Bach, A; Ferger, B; Kuner, R; Naim, J; Richter, A; Schmidt, N; Schneider, A; Teismann, P; Trutzel, A, 2004) |
| "We developed a primate model of striatonigral degeneration (SND), the neuropathology underlying levodopa-unresponsive parkinsonism associated with multiple systemic atrophy (MSA-P), by sequential systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionic acid (3NP) in a Macaca fascicularis monkey." | 1.31 | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. ( Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK, 2000) |
| " The lower dosages of (+/-)-kavain (50 and 100 mg/kg) showed only a nonsignificant attenuation of MPTP-induced dopamine depletion, but a high dosage of (+/-)-kavain (200 mg/kg) significantly antagonized the dopamine depletion to 58." | 1.31 | Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. ( Ferger, B; Schmidt, N, 2001) |
| " Neuronal degeneration was observed in the substantia nigra pars compacta (SN), ventral tegmental area (VTA) and retrorubral field (RRF) of only animals dosed in the low temperature environment." | 1.30 | Systemic administration of MPTP induces thalamic neuronal degeneration in mice. ( Ali, SF; Freyaldenhoven, TE; Schmued, LC, 1997) |
| " MPTP-treated mice maintained at 4 degrees C demonstrated (1) a greater hypothermic response, (2) a significant reduction in striatal DA content and tyrosine hydroxylase (TH) activity, and (3) significantly greater striatal 1-methyl-4-phenylpyridinium (MPP+) levels, as compared to mice dosed with MPTP at room temperature." | 1.30 | Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice. ( Albers, DS; Moy, LY; Sonsalla, PK, 1998) |
| "Modafinil treatment dose-dependently (10-100 mg/kg) counteracted the hemitransection-induced disappearance of nigral TH-immunoreactive nerve cell body profiles and neostriatal TH-immunoreactive nerve terminal profiles." | 1.29 | The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway. ( Agnati, LF; Altamimi, U; Andbjer, B; Finnman, UB; Fuxe, K; Goldstein, M; Janson, AM; Rosén, L; Ueki, A, 1993) |
| "In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra." | 1.27 | Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. ( Agid, YA; Graybiel, AM; Hirsch, E, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (6.90) | 18.7374 |
| 1990's | 36 (17.73) | 18.2507 |
| 2000's | 83 (40.89) | 29.6817 |
| 2010's | 63 (31.03) | 24.3611 |
| 2020's | 7 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Pereira, MCL | 1 |
| Boese, AC | 1 |
| Murad, R | 1 |
| Yin, J | 1 |
| Hamblin, MH | 1 |
| Lee, JP | 1 |
| Palese, F | 1 |
| Pontis, S | 2 |
| Realini, N | 1 |
| Torrens, A | 1 |
| Ahmed, F | 1 |
| Assogna, F | 1 |
| Pellicano, C | 1 |
| Bossù, P | 1 |
| Spalletta, G | 1 |
| Green, K | 1 |
| Piomelli, D | 1 |
| Edwards Iii, G | 1 |
| Gamez, N | 1 |
| Armijo, E | 1 |
| Kramm, C | 1 |
| Morales, R | 1 |
| Taylor-Presse, K | 1 |
| Schulz, PE | 1 |
| Soto, C | 1 |
| Moreno-Gonzalez, I | 1 |
| He, X | 1 |
| Yang, L | 2 |
| Huang, R | 1 |
| Lin, L | 1 |
| Shen, Y | 1 |
| Cheng, L | 1 |
| Jin, L | 1 |
| Wang, S | 1 |
| Zhu, R | 1 |
| Yang, Y | 1 |
| Kong, F | 1 |
| Ding, Q | 1 |
| Cai, Y | 1 |
| Hao, Y | 1 |
| Tang, B | 1 |
| Zhang, Y | 4 |
| Qin, L | 1 |
| Xie, J | 2 |
| Li, J | 2 |
| Wang, C | 1 |
| Yang, W | 1 |
| Hao, W | 1 |
| Meng, Z | 1 |
| Ding, S | 1 |
| Li, X | 2 |
| Zhang, T | 2 |
| Huang, W | 1 |
| Xu, L | 1 |
| Yang, J | 2 |
| Gu, X | 1 |
| Ou, Z | 1 |
| Zhou, Y | 3 |
| Wang, L | 1 |
| Xue, L | 1 |
| Zheng, J | 1 |
| Chen, L | 2 |
| Tong, Q | 1 |
| Gotsbacher, MP | 1 |
| Telfer, TJ | 1 |
| Witting, PK | 1 |
| Double, KL | 1 |
| Finkelstein, DI | 1 |
| Codd, R | 1 |
| Alieva, AK | 1 |
| Zyrin, VS | 1 |
| Rudenok, MM | 1 |
| Kolacheva, AA | 1 |
| Shulskaya, MV | 1 |
| Ugryumov, MV | 1 |
| Slominsky, PA | 1 |
| Shadrina, MI | 1 |
| Rosa, AI | 1 |
| Duarte-Silva, S | 1 |
| Silva-Fernandes, A | 1 |
| Nunes, MJ | 1 |
| Carvalho, AN | 2 |
| Rodrigues, E | 3 |
| Gama, MJ | 3 |
| Rodrigues, CMP | 1 |
| Maciel, P | 1 |
| Castro-Caldas, M | 3 |
| Ren, Q | 1 |
| Ma, M | 1 |
| Nonaka, R | 1 |
| Yamaguchi, A | 1 |
| Ishikawa, KI | 1 |
| Kobayashi, K | 1 |
| Murayama, S | 1 |
| Hwang, SH | 1 |
| Saiki, S | 1 |
| Akamatsu, W | 1 |
| Hattori, N | 2 |
| Hammock, BD | 1 |
| Hashimoto, K | 1 |
| Togashi, K | 1 |
| Hasegawa, M | 1 |
| Nagai, J | 1 |
| Tonouchi, A | 1 |
| Masukawa, D | 1 |
| Hensley, K | 1 |
| Goshima, Y | 1 |
| Ohshima, T | 1 |
| Hu, ZL | 1 |
| Sun, T | 1 |
| Lu, M | 1 |
| Ding, JH | 1 |
| Du, RH | 1 |
| Hu, G | 2 |
| Hu, YB | 1 |
| Zhang, YF | 1 |
| Wang, H | 1 |
| Ren, RJ | 1 |
| Cui, HL | 1 |
| Huang, WY | 1 |
| Cheng, Q | 1 |
| Chen, HZ | 1 |
| Wang, G | 2 |
| Zhu, G | 1 |
| Wang, X | 1 |
| Wu, S | 1 |
| Li, Q | 2 |
| Breckenridge, CB | 1 |
| Sturgess, NC | 1 |
| Butt, M | 1 |
| Wolf, JC | 1 |
| Zadory, D | 1 |
| Beck, M | 1 |
| Mathews, JM | 1 |
| Tisdel, MO | 1 |
| Minnema, D | 1 |
| Travis, KZ | 1 |
| Cook, AR | 1 |
| Botham, PA | 1 |
| Smith, LL | 1 |
| González, H | 1 |
| Contreras, F | 1 |
| Prado, C | 1 |
| Elgueta, D | 1 |
| Franz, D | 1 |
| Bernales, S | 1 |
| Pacheco, R | 1 |
| Cartelli, D | 1 |
| Casagrande, F | 1 |
| Busceti, CL | 2 |
| Bucci, D | 2 |
| Molinaro, G | 2 |
| Traficante, A | 2 |
| Passarella, D | 1 |
| Giavini, E | 1 |
| Pezzoli, G | 1 |
| Battaglia, G | 2 |
| Cappelletti, G | 2 |
| Campello, L | 1 |
| Esteve-Rudd, J | 1 |
| Bru-Martínez, R | 1 |
| Herrero, MT | 6 |
| Fernández-Villalba, E | 3 |
| Cuenca, N | 1 |
| Martín-Nieto, J | 1 |
| Borrajo, A | 1 |
| Rodriguez-Perez, AI | 1 |
| Diaz-Ruiz, C | 1 |
| Guerra, MJ | 2 |
| Labandeira-Garcia, JL | 3 |
| Youn, JK | 1 |
| Kim, DW | 2 |
| Kim, ST | 1 |
| Park, SY | 1 |
| Yeo, EJ | 1 |
| Choi, YJ | 1 |
| Lee, HR | 1 |
| Kim, DS | 2 |
| Cho, SW | 2 |
| Han, KH | 2 |
| Park, J | 2 |
| Eum, WS | 2 |
| Hwang, HS | 2 |
| Choi, SY | 2 |
| Sohn, EJ | 1 |
| Shin, MJ | 1 |
| Ahn, EH | 1 |
| Jo, HS | 1 |
| Yun, HM | 1 |
| Choi, DY | 2 |
| Oh, KW | 2 |
| Hong, JT | 2 |
| Jin, H | 1 |
| Kanthasamy, A | 2 |
| Harischandra, DS | 1 |
| Anantharam, V | 1 |
| Rana, A | 1 |
| Liu, L | 4 |
| Peritore, C | 1 |
| Ginsberg, J | 1 |
| Shih, J | 1 |
| Arun, S | 1 |
| Donmez, G | 1 |
| Kinoshita, K | 1 |
| Tada, Y | 1 |
| Muroi, Y | 1 |
| Unno, T | 1 |
| Ishii, T | 1 |
| Xu, X | 1 |
| Song, N | 1 |
| Wang, R | 1 |
| Jiang, H | 1 |
| Muñoz-Manchado, AB | 1 |
| Villadiego, J | 1 |
| Romo-Madero, S | 1 |
| Suárez-Luna, N | 1 |
| Bermejo-Navas, A | 1 |
| Rodríguez-Gómez, JA | 1 |
| Garrido-Gil, P | 2 |
| Echevarría, M | 1 |
| López-Barneo, J | 1 |
| Toledo-Aral, JJ | 1 |
| Zhang, J | 2 |
| Yang, B | 1 |
| Sun, H | 1 |
| Liu, M | 1 |
| Ding, J | 2 |
| Fang, F | 1 |
| Fan, Y | 1 |
| Hwang, CJ | 1 |
| Jung, YY | 1 |
| Lee, YJ | 1 |
| Yun, JS | 1 |
| Han, SB | 1 |
| Oh, S | 1 |
| Park, MH | 1 |
| Luo, D | 1 |
| Shi, Y | 1 |
| Wang, J | 1 |
| Lin, Q | 1 |
| Sun, Y | 1 |
| Ye, K | 1 |
| Yan, Q | 1 |
| Zhang, H | 1 |
| Zhang, Z | 1 |
| Jiang, X | 1 |
| Zhai, S | 1 |
| Xing, D | 1 |
| Yu, C | 1 |
| Kim, BS | 1 |
| Kim, E | 1 |
| Paul, R | 1 |
| Choudhury, A | 1 |
| Kumar, S | 2 |
| Giri, A | 1 |
| Sandhir, R | 1 |
| Borah, A | 1 |
| Belloli, S | 1 |
| Pannese, M | 1 |
| Buonsanti, C | 1 |
| Maiorino, C | 1 |
| Di Grigoli, G | 1 |
| Carpinelli, A | 1 |
| Monterisi, C | 1 |
| Moresco, RM | 1 |
| Panina-Bordignon, P | 1 |
| Ho, G | 1 |
| Zhang, C | 1 |
| Kng, YL | 1 |
| Zhuo, L | 1 |
| Alvarez-Fischer, D | 1 |
| Guerreiro, S | 1 |
| Hunot, S | 1 |
| Saurini, F | 1 |
| Marien, M | 1 |
| Sokoloff, P | 1 |
| Hirsch, EC | 5 |
| Hartmann, A | 1 |
| Michel, PP | 1 |
| Neves Carvalho, A | 1 |
| Peixeiro, I | 1 |
| Lechner, MC | 1 |
| Samantaray, S | 2 |
| Butler, JT | 2 |
| Ray, SK | 2 |
| Banik, NL | 2 |
| Sado, M | 1 |
| Yamasaki, Y | 1 |
| Iwanaga, T | 1 |
| Onaka, Y | 1 |
| Ibuki, T | 1 |
| Nishihara, S | 1 |
| Mizuguchi, H | 1 |
| Momota, H | 1 |
| Kishibuchi, R | 1 |
| Hashimoto, T | 1 |
| Wada, D | 1 |
| Kitagawa, H | 1 |
| Watanabe, TK | 1 |
| Pothakos, K | 2 |
| Kurz, MJ | 2 |
| Lau, YS | 3 |
| Lagrue, E | 1 |
| Abert, B | 1 |
| Nadal, L | 1 |
| Tabone, L | 1 |
| Bodard, S | 1 |
| Medja, F | 1 |
| Lombes, A | 1 |
| Chalon, S | 1 |
| Castelnau, P | 1 |
| Moon, M | 1 |
| Kim, HG | 1 |
| Hwang, L | 1 |
| Seo, JH | 1 |
| Kim, S | 2 |
| Hwang, S | 1 |
| Lee, D | 1 |
| Chung, H | 1 |
| Oh, MS | 1 |
| Lee, KT | 1 |
| Park, S | 1 |
| Marazziti, D | 1 |
| Di Pietro, C | 1 |
| Golini, E | 1 |
| Mandillo, S | 1 |
| Matteoni, R | 1 |
| Tocchini-Valentini, GP | 1 |
| Gibrat, C | 1 |
| Saint-Pierre, M | 1 |
| Bousquet, M | 2 |
| Lévesque, D | 1 |
| Rouillard, C | 1 |
| Cicchetti, F | 3 |
| Rolland, AS | 1 |
| Tandé, D | 1 |
| Luquin, MR | 2 |
| Vazquez-Claverie, M | 2 |
| Karachi, C | 1 |
| François, C | 1 |
| Bian, MJ | 1 |
| Li, LM | 1 |
| Yu, M | 1 |
| Fei, J | 1 |
| Huang, F | 1 |
| San Sebastián, W | 1 |
| Izal-Azcárate, A | 1 |
| Belzunegui, S | 1 |
| Marcilla, I | 1 |
| López, B | 1 |
| Pinna, A | 1 |
| Tronci, E | 1 |
| Schintu, N | 1 |
| Simola, N | 1 |
| Volpini, R | 1 |
| Cristalli, G | 1 |
| Morelli, M | 1 |
| Yokoyama, H | 3 |
| Kuroiwa, H | 3 |
| Tsukada, T | 3 |
| Uchida, H | 3 |
| Kato, H | 4 |
| Araki, T | 5 |
| Wang, WF | 1 |
| Wu, SL | 1 |
| Liou, YM | 1 |
| Wang, AL | 1 |
| Pawlak, CR | 1 |
| Ho, YJ | 1 |
| Pan, J | 1 |
| Qian, J | 1 |
| Ma, J | 1 |
| Xiao, Q | 1 |
| Chen, S | 1 |
| Cano-Jaimez, M | 1 |
| Pérez-Sánchez, F | 1 |
| Milán, M | 1 |
| Buendía, P | 1 |
| Ambrosio, S | 1 |
| Fariñas, I | 1 |
| Gerecke, KM | 1 |
| Jiao, Y | 2 |
| Pani, A | 1 |
| Pagala, V | 1 |
| Smeyne, RJ | 4 |
| Xu, G | 2 |
| Xiong, Z | 2 |
| Yong, Y | 1 |
| Wang, Z | 1 |
| Ke, Z | 2 |
| Xia, Z | 3 |
| Hu, Y | 2 |
| Corona, JC | 1 |
| Gimenez-Cassina, A | 1 |
| Lim, F | 1 |
| Díaz-Nido, J | 1 |
| Yu, S | 2 |
| Zheng, W | 1 |
| Xin, N | 1 |
| Chi, ZH | 1 |
| Wang, NQ | 1 |
| Nie, YX | 1 |
| Feng, WY | 1 |
| Wang, ZY | 1 |
| Yano, R | 3 |
| Kasahara, J | 2 |
| Biju, K | 1 |
| Zhou, Q | 1 |
| Li, G | 1 |
| Imam, SZ | 1 |
| Roberts, JL | 1 |
| Morgan, WW | 1 |
| Clark, RA | 1 |
| Li, S | 1 |
| Liu, J | 2 |
| Wang, MW | 1 |
| Gu, P | 1 |
| Ma, QY | 1 |
| Wang, YY | 1 |
| Geng, Y | 1 |
| Yuan, ZY | 1 |
| Cui, DS | 1 |
| Zhang, ZX | 1 |
| Ma, L | 1 |
| Zhang, BH | 1 |
| Zhou, MG | 1 |
| Zhu, AP | 1 |
| Huang, YM | 1 |
| Yin, ZQ | 1 |
| Tanriover, G | 1 |
| Seval-Celik, Y | 1 |
| Ozsoy, O | 1 |
| Akkoyunlu, G | 1 |
| Savcioglu, F | 1 |
| Hacioglu, G | 1 |
| Demir, N | 1 |
| Agar, A | 1 |
| Steidinger, TU | 1 |
| Standaert, DG | 1 |
| Yacoubian, TA | 1 |
| Chung, YC | 1 |
| Kim, SR | 2 |
| Park, JY | 2 |
| Chung, ES | 1 |
| Park, KW | 1 |
| Won, SY | 1 |
| Bok, E | 1 |
| Jin, M | 1 |
| Park, ES | 2 |
| Yoon, SH | 1 |
| Ko, HW | 1 |
| Kim, YS | 1 |
| Jin, BK | 2 |
| Côté, M | 1 |
| Drouin-Ouellet, J | 1 |
| Soulet, D | 1 |
| Masilamoni, GJ | 1 |
| Bogenpohl, JW | 1 |
| Alagille, D | 1 |
| Delevich, K | 1 |
| Tamagnan, G | 1 |
| Votaw, JR | 1 |
| Wichmann, T | 1 |
| Smith, Y | 1 |
| Yasuda, T | 1 |
| Hayakawa, H | 1 |
| Nihira, T | 1 |
| Ren, YR | 1 |
| Nakata, Y | 1 |
| Nagai, M | 1 |
| Miyake, K | 1 |
| Takada, M | 1 |
| Shimada, T | 1 |
| Mizuno, Y | 2 |
| Mochizuki, H | 1 |
| Shchepinov, MS | 1 |
| Chou, VP | 1 |
| Pollock, E | 1 |
| Langston, JW | 8 |
| Cantor, CR | 1 |
| Molinari, RJ | 1 |
| Manning-Boğ, AB | 2 |
| St-Amour, I | 1 |
| Vandal, M | 1 |
| Julien, P | 1 |
| Calon, F | 1 |
| Kim, SN | 1 |
| Doo, AR | 1 |
| Bae, H | 1 |
| Chae, Y | 1 |
| Shim, I | 1 |
| Lee, H | 2 |
| Moon, W | 1 |
| Park, HJ | 1 |
| Sun, X | 1 |
| Meng, Y | 1 |
| Zhang, R | 1 |
| Khaindrava, VG | 1 |
| Kozina, EA | 1 |
| Kudrin, VS | 1 |
| Kucheryanu, VG | 1 |
| Klodt, PD | 1 |
| Narkevich, VB | 1 |
| Bocharov, EV | 1 |
| Nanaev, AK | 1 |
| Kryzhanovsky, GN | 1 |
| Raevskii, KS | 1 |
| Ugrumov, MV | 1 |
| Nagai, Y | 1 |
| Minamimoto, T | 1 |
| Ando, K | 1 |
| Obayashi, S | 1 |
| Ito, H | 1 |
| Ito, N | 1 |
| Suhara, T | 1 |
| Haque, ME | 1 |
| Mount, MP | 1 |
| Safarpour, F | 1 |
| Abdel-Messih, E | 1 |
| Callaghan, S | 1 |
| Mazerolle, C | 1 |
| Kitada, T | 1 |
| Slack, RS | 1 |
| Wallace, V | 1 |
| Shen, J | 1 |
| Anisman, H | 1 |
| Park, DS | 1 |
| Vivacqua, G | 1 |
| Biagioni, F | 2 |
| Casini, A | 1 |
| D'Este, L | 1 |
| Fornai, F | 2 |
| Tasaki, Y | 1 |
| Yamamoto, J | 1 |
| Omura, T | 1 |
| Sakaguchi, T | 1 |
| Kimura, N | 1 |
| Ohtaki, K | 1 |
| Ono, T | 1 |
| Suno, M | 1 |
| Asari, M | 1 |
| Ohkubo, T | 1 |
| Noda, T | 1 |
| Awaya, T | 1 |
| Shimizu, K | 1 |
| Matsubara, K | 1 |
| Henderson, CJ | 1 |
| Wolf, CR | 1 |
| Rodrigues, CM | 1 |
| Tanaka, M | 1 |
| Yamaguchi, E | 1 |
| Takahashi, M | 1 |
| Hashimura, K | 1 |
| Shibata, T | 1 |
| Nakamura, W | 1 |
| Nakamura, TJ | 1 |
| Wang, XH | 1 |
| Lu, G | 1 |
| Hu, X | 1 |
| Tsang, KS | 1 |
| Kwong, WH | 1 |
| Wu, FX | 1 |
| Meng, HW | 1 |
| Jiang, S | 1 |
| Liu, SW | 1 |
| Ng, HK | 1 |
| Poon, WS | 1 |
| Luk, KC | 1 |
| Rymar, VV | 1 |
| van den Munckhof, P | 1 |
| Nicolau, S | 1 |
| Steriade, C | 1 |
| Bifsha, P | 1 |
| Drouin, J | 1 |
| Sadikot, AF | 1 |
| Phani, S | 1 |
| Jablonski, M | 1 |
| Pelta-Heller, J | 1 |
| Cai, J | 1 |
| Iacovitti, L | 1 |
| Steindler, DA | 1 |
| Di Monte, DA | 3 |
| Lavasani, M | 1 |
| Ryan, RW | 1 |
| Post, JI | 1 |
| Solc, M | 1 |
| Hodson, PV | 1 |
| Ross, GM | 1 |
| Sugama, S | 2 |
| Cho, BP | 1 |
| DeGiorgio, LA | 1 |
| Lorenzl, S | 1 |
| Albers, DS | 2 |
| Beal, MF | 2 |
| Volpe, BT | 1 |
| Joh, TH | 1 |
| Muramatsu, Y | 1 |
| Kurosaki, R | 1 |
| Watanabe, H | 1 |
| Michimata, M | 1 |
| Matsubara, M | 1 |
| Imai, Y | 1 |
| Gao, HM | 1 |
| Liu, B | 1 |
| Zhang, W | 2 |
| Hong, JS | 2 |
| He, Y | 1 |
| Thong, PS | 1 |
| Lee, T | 1 |
| Leong, SK | 1 |
| Mao, BY | 1 |
| Dong, F | 1 |
| Watt, F | 1 |
| Youdim, MB | 4 |
| Höglinger, G | 1 |
| Rousselet, E | 1 |
| Breidert, T | 1 |
| Parain, K | 1 |
| Feger, J | 1 |
| Ruberg, M | 1 |
| Prigent, A | 1 |
| Cohen-Salmon, C | 1 |
| Launay, JM | 1 |
| Hsu, SS | 1 |
| Kalia, SK | 1 |
| Lozano, AM | 1 |
| Aguilar Hernández, R | 1 |
| Sánchez De Las Matas, MJ | 1 |
| Arriagada, C | 1 |
| Barcia, C | 3 |
| Caviedes, P | 1 |
| Segura-Aguilar, J | 1 |
| Kuner, R | 1 |
| Teismann, P | 2 |
| Trutzel, A | 1 |
| Naim, J | 1 |
| Richter, A | 1 |
| Schmidt, N | 2 |
| Bach, A | 1 |
| Ferger, B | 3 |
| Schneider, A | 1 |
| Song, DD | 1 |
| Shults, CW | 1 |
| Sisk, A | 1 |
| Rockenstein, E | 1 |
| Masliah, E | 1 |
| Sánchez Bahillo, A | 1 |
| Bautista, V | 1 |
| Poza Y Poza, M | 1 |
| Fernández-Barreiro, A | 2 |
| Kurkowska-Jastrzebska, I | 2 |
| Litwin, T | 1 |
| Joniec, I | 1 |
| Ciesielska, A | 1 |
| Przybyłkowski, A | 1 |
| Członkowski, A | 2 |
| Członkowska, A | 3 |
| Wirz, SA | 1 |
| Barr, AM | 1 |
| Conti, B | 1 |
| Bartfai, T | 1 |
| Shibasaki, T | 1 |
| Dong, Z | 1 |
| Wolfer, DP | 1 |
| Lipp, HP | 1 |
| Büeler, H | 1 |
| Abdel-Wahab, MH | 1 |
| Faherty, CJ | 1 |
| Raviie Shepherd, K | 1 |
| Herasimtschuk, A | 1 |
| Holmer, HK | 1 |
| Keyghobadi, M | 1 |
| Moore, C | 1 |
| Menashe, RA | 1 |
| Meshul, CK | 1 |
| Ostergren, A | 1 |
| Fredriksson, A | 1 |
| Brittebo, EB | 1 |
| Bassilana, F | 1 |
| Mace, N | 1 |
| Stutzmann, JM | 1 |
| Gross, CE | 2 |
| Pradier, L | 1 |
| Benavides, J | 1 |
| Ménager, J | 1 |
| Bezard, E | 4 |
| de Pablos, V | 1 |
| Bautista-Hernández, V | 1 |
| Sánchez-Bahillo, A | 1 |
| Bernal, I | 1 |
| Martín, J | 1 |
| Bañón, R | 1 |
| McKinley, ET | 1 |
| Baranowski, TC | 1 |
| Blavo, DO | 1 |
| Cato, C | 1 |
| Doan, TN | 1 |
| Rubinstein, AL | 1 |
| Marti, M | 1 |
| Mela, F | 1 |
| Fantin, M | 1 |
| Zucchini, S | 1 |
| Brown, JM | 1 |
| Witta, J | 1 |
| Di Benedetto, M | 1 |
| Buzas, B | 1 |
| Reinscheid, RK | 1 |
| Salvadori, S | 1 |
| Guerrini, R | 1 |
| Romualdi, P | 1 |
| Candeletti, S | 1 |
| Simonato, M | 1 |
| Cox, BM | 1 |
| Morari, M | 1 |
| Luellen, BA | 1 |
| Szapacs, ME | 1 |
| Materese, CK | 1 |
| Andrews, AM | 1 |
| Morale, MC | 1 |
| Serra, PA | 1 |
| L'episcopo, F | 1 |
| Tirolo, C | 1 |
| Caniglia, S | 1 |
| Testa, N | 1 |
| Gennuso, F | 1 |
| Giaquinta, G | 1 |
| Rocchitta, G | 1 |
| Desole, MS | 1 |
| Miele, E | 1 |
| Marchetti, B | 1 |
| McLaughlin, P | 1 |
| Ma, T | 1 |
| Kovacs, M | 1 |
| Novikova, L | 2 |
| Garris, BL | 1 |
| Garris, DR | 1 |
| Ohashi, S | 1 |
| Mori, A | 1 |
| Kurihara, N | 1 |
| Mitsumoto, Y | 1 |
| Nakai, M | 1 |
| Wang, JJ | 1 |
| Niu, DB | 1 |
| Wang, K | 1 |
| Li, KR | 1 |
| Xue, B | 1 |
| Wang, XM | 1 |
| Quinn, LP | 1 |
| Stean, TO | 1 |
| Chapman, H | 1 |
| Brown, M | 1 |
| Vidgeon-Hart, M | 1 |
| Upton, N | 1 |
| Billinton, A | 1 |
| Virley, DJ | 1 |
| Kaur, D | 2 |
| Rajagopalan, S | 2 |
| Chinta, S | 1 |
| Kumar, J | 1 |
| Di Monte, D | 2 |
| Cherny, RA | 2 |
| Andersen, JK | 2 |
| Muñoz, A | 1 |
| Rey, P | 1 |
| Mendez-Alvarez, E | 1 |
| Soto-Otero, R | 1 |
| Teng, X | 1 |
| Sakai, T | 1 |
| Sakai, R | 1 |
| Kaji, R | 1 |
| Fukui, K | 1 |
| Carvey, PM | 1 |
| Punati, A | 1 |
| Newman, MB | 1 |
| Soderstrom, K | 1 |
| O'Malley, J | 1 |
| Steece-Collier, K | 1 |
| Kordower, JH | 2 |
| Peng, J | 1 |
| Chinta, SJ | 1 |
| Nicoletti, F | 1 |
| Bruno, V | 1 |
| Quik, M | 2 |
| Parameswaran, N | 1 |
| McCallum, SE | 1 |
| Bordia, T | 1 |
| Bao, S | 1 |
| McCormack, A | 1 |
| Kim, A | 1 |
| Tyndale, RF | 1 |
| von Bohlen und Halbach, O | 1 |
| Schober, A | 2 |
| Hertel, R | 1 |
| Unsicker, K | 2 |
| Schmidt, WJ | 1 |
| Alam, M | 1 |
| Sagi, Y | 1 |
| Mandel, S | 4 |
| Amit, T | 1 |
| Peterziel, H | 1 |
| von Bartheld, CS | 1 |
| Simon, H | 1 |
| Krieglstein, K | 1 |
| Anderson, DW | 1 |
| Bradbury, KA | 1 |
| Schneider, JS | 1 |
| Pattarini, R | 1 |
| Morgan, JI | 1 |
| Bian, GL | 1 |
| Wei, LC | 1 |
| Shi, M | 1 |
| Wang, YQ | 1 |
| Cao, R | 1 |
| Chen, LW | 1 |
| Sawada, H | 1 |
| Hishida, R | 1 |
| Hirata, Y | 1 |
| Ono, K | 1 |
| Suzuki, H | 1 |
| Muramatsu, S | 1 |
| Nakano, I | 1 |
| Nagatsu, T | 1 |
| Sawada, M | 1 |
| Al-Jarrah, M | 1 |
| Smirnova, IV | 1 |
| Stehno-Bittel, L | 1 |
| Rojo, AI | 1 |
| Cavada, C | 1 |
| de Sagarra, MR | 1 |
| Cuadrado, A | 1 |
| Boyd, JD | 1 |
| Jang, H | 1 |
| Shepherd, KR | 1 |
| Faherty, C | 1 |
| Slack, S | 1 |
| Mocchetti, I | 1 |
| Bachis, A | 1 |
| Nosheny, RL | 1 |
| Tanda, G | 1 |
| Knaryan, VH | 1 |
| van Vliet, SA | 1 |
| van Vlieta, SA | 1 |
| Blezer, EL | 1 |
| Jongsma, MJ | 1 |
| Vanwersch, RA | 1 |
| Olivier, B | 1 |
| Philippens, IH | 1 |
| Ding, Y | 1 |
| Cagniard, B | 1 |
| Van Laar, AD | 1 |
| Mortimer, A | 1 |
| Chi, W | 1 |
| Hastings, TG | 1 |
| Kang, UJ | 1 |
| Zhuang, X | 1 |
| Rajeswari, A | 1 |
| Sabesan, M | 1 |
| Kadoguchi, N | 1 |
| Kimoto, H | 1 |
| Tomac, A | 1 |
| Lindqvist, E | 1 |
| Lin, LF | 1 |
| Ogren, SO | 1 |
| Young, D | 1 |
| Hoffer, BJ | 1 |
| Olson, L | 1 |
| Löschmann, PA | 1 |
| Lange, KW | 1 |
| Wachtel, H | 1 |
| Turski, L | 1 |
| Edwards, RH | 1 |
| Ueki, A | 1 |
| Rosén, L | 1 |
| Andbjer, B | 1 |
| Finnman, UB | 1 |
| Altamimi, U | 1 |
| Janson, AM | 3 |
| Goldstein, M | 4 |
| Agnati, LF | 3 |
| Fuxe, K | 3 |
| Oishi, T | 1 |
| Hasegawa, E | 1 |
| Murai, Y | 1 |
| Miletich, RS | 1 |
| Bankiewicz, KS | 1 |
| Quarantelli, M | 1 |
| Plunkett, RJ | 1 |
| Frank, J | 1 |
| Kopin, IJ | 1 |
| Di Chiro, G | 1 |
| Tatton, WG | 1 |
| Rinne, JO | 1 |
| Poirier, J | 1 |
| Thiffault, C | 1 |
| Chiueh, CC | 1 |
| Miyake, H | 1 |
| Peng, MT | 1 |
| Singer, TP | 1 |
| Ramsay, RR | 1 |
| Sonsalla, PK | 5 |
| Nicklas, WJ | 1 |
| Heikkila, RE | 1 |
| Mash, DC | 1 |
| Sanchez-Ramos, J | 1 |
| Weiner, WJ | 1 |
| Bieganowska, K | 1 |
| Bidziński, A | 1 |
| Mierzewska, H | 1 |
| Korlak, J | 1 |
| Tsukahara, T | 1 |
| Takeda, M | 1 |
| Shimohama, S | 1 |
| Ohara, O | 1 |
| Hashimoto, N | 1 |
| Faucheux, BA | 1 |
| Villares, J | 1 |
| Levy, R | 1 |
| Javoy-Agid, F | 1 |
| Obeso, JA | 1 |
| Hauw, JJ | 1 |
| Agid, Y | 1 |
| Schmued, LC | 2 |
| Albertson, C | 1 |
| Slikker, W | 1 |
| German, DC | 3 |
| Nelson, EL | 1 |
| Liang, CL | 3 |
| Speciale, SG | 1 |
| Sinton, CM | 2 |
| Freyaldenhoven, TE | 1 |
| Ali, SF | 1 |
| Lan, J | 1 |
| Jiang, DH | 1 |
| Dovero, S | 2 |
| Bioulac, B | 2 |
| Gross, C | 1 |
| Marcotte, ER | 1 |
| Chugh, A | 1 |
| Mishra, RK | 1 |
| Johnson, RL | 1 |
| Moy, LY | 1 |
| Brownell, AL | 1 |
| Jenkins, BG | 1 |
| Elmaleh, DR | 1 |
| Deacon, TW | 1 |
| Spealman, RD | 1 |
| Isacson, O | 2 |
| Spratt, C | 1 |
| Seitz, G | 1 |
| Kuschinsky, K | 1 |
| Saporito, MS | 1 |
| Brown, EM | 1 |
| Miller, MS | 1 |
| Carswell, S | 1 |
| Leonardi, ET | 1 |
| Mytilineou, C | 1 |
| Forno, LS | 4 |
| Tetrud, J | 1 |
| Reeves, AG | 1 |
| Kaplan, JA | 1 |
| Karluk, D | 1 |
| Grünblatt, E | 2 |
| Lewandowska, E | 1 |
| Lechowicz, W | 1 |
| Kim, H | 1 |
| Jhoo, W | 1 |
| Shin, E | 1 |
| Bing, G | 1 |
| Ghorayeb, I | 1 |
| Fernagut, PO | 1 |
| Aubert, I | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Tison, F | 1 |
| Annepu, J | 1 |
| Ravindranath, V | 1 |
| Polonskaya, Y | 1 |
| Gillespie, A | 1 |
| K Lloyd, G | 1 |
| Emborg, ME | 1 |
| Bloch, J | 1 |
| Ma, SY | 1 |
| Chu, Y | 1 |
| Leventhal, L | 1 |
| McBride, J | 1 |
| Chen, EY | 1 |
| Palfi, S | 1 |
| Roitberg, BZ | 1 |
| Brown, WD | 1 |
| Holden, JE | 1 |
| Pyzalski, R | 1 |
| Taylor, MD | 1 |
| Carvey, P | 1 |
| Ling, Z | 1 |
| Trono, D | 1 |
| Hantraye, P | 1 |
| Déglon, N | 1 |
| Aebischer, P | 1 |
| Manaye, KF | 1 |
| Lane, K | 1 |
| Youdim, M | 1 |
| Costantini, LC | 1 |
| Cole, D | 1 |
| Chaturvedi, P | 1 |
| Levites, Y | 1 |
| Weinreb, O | 1 |
| Maor, G | 1 |
| Pedrotti, B | 1 |
| Maggioni, MG | 1 |
| Maci, R | 1 |
| Ikeda, K | 1 |
| Kurokawa, M | 1 |
| Aoyama, S | 1 |
| Kuwana, Y | 1 |
| DeLanney, LE | 3 |
| Irwin, I | 3 |
| Bachurin, SO | 1 |
| Sablin, SO | 1 |
| Lermontova, NN | 1 |
| Solyakov, LS | 1 |
| Dubova, LG | 1 |
| Tkachenko, SE | 1 |
| Zuddas, A | 1 |
| Oberto, G | 1 |
| Vaglini, F | 1 |
| Fascetti, F | 1 |
| Corsini, GU | 1 |
| Taylor, R | 1 |
| Miyoshi, R | 1 |
| Kito, S | 1 |
| Ishida, H | 1 |
| Katayama, S | 1 |
| Hirsch, E | 1 |
| Graybiel, AM | 1 |
| Agid, YA | 1 |
| Sundström, E | 4 |
| Luthman, J | 2 |
| Jonsson, G | 3 |
| Cintra, A | 1 |
| Zini, I | 1 |
| Toffano, G | 1 |
| Donaldson, J | 1 |
| Ricaurte, GA | 2 |
| Peroutka, SJ | 1 |
| Langston, E | 1 |
| Willis, GL | 1 |
| Savulescu, J | 1 |
| Horne, MK | 1 |
| Smith, GC | 1 |
| Wilson, JS | 1 |
| Turner, BH | 1 |
| Morrow, GD | 1 |
| Hartman, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA[NCT04899206] | 120 participants (Anticipated) | Observational [Patient Registry] | 2021-04-12 | Active, not recruiting | |||
| A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)[NCT03840005] | Phase 2 | 31 participants (Actual) | Interventional | 2018-12-18 | Completed | ||
| [NCT01502384] | 100 participants (Anticipated) | Observational | 2012-01-31 | Not yet recruiting | |||
| Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)[NCT02008721] | Phase 3 | 92 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Nerve Degeneration
| Article | Year |
|---|---|
Environmental factors in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Environment; Humans; Nerve D | 2002 |
What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Cell Death; Dopamine; | 2003 |
Animal models of Parkinson's disease in rodents induced by toxins: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Basal Ganglia; Brain Stem; | 2003 |
Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Humans; In | 2006 |
Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Disease Models, Animal; Disease Progre | 2006 |
Neural repair strategies for Parkinson's disease: insights from primate models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Transplantation; Deep Brain Stimulation; | 2006 |
Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Dopamine Agents; Humans; Nerve Dege | 2006 |
Neural degeneration and the transport of neurotransmitters.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amyotrophic Lateral Sclerosis; Animals; Biological Tra | 1993 |
Selegiline can mediate neuronal rescue rather than neuronal protection.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Isoenzymes; Mice; Mice, Inbred BALB | 1993 |
Nigral degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Haplorhini; Humans; Isoenzymes; Mon | 1993 |
Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalase; Corpus Striatum; Free Radicals; Glu | 1993 |
Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism. New vistas.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Humans; MPTP Poisoning; NAD(P) | 1993 |
Transferrin receptor regulation in Parkinson's disease and MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Dopamine Plasma Membrane Tr | 1993 |
Metabolic disorders and neurotoxicology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Humans; Metabolic Diseases; Nerve D | 1995 |
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Disease | 1997 |
Cell culture models of neuronal degeneration and neuroprotection. Implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Culture Techniques; Dopamine; Growth Sub | 1998 |
Astrocytes and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biotransformation; Dopamine; Glio | 1992 |
Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Survival; Free Radicals; Humans; | 1989 |
[Contribution of MPTP to studies on the pathogenesis of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electron Transport; Mice; Mitochondria; Nerve | 1989 |
The physiopathologic significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Brain; Brain Chemistry; Chile; | 1987 |
183 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Nerve Degeneration
| Article | Year |
|---|---|
Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2022 |
Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidohydrolases; Animals; Disease Models, Animal; Dopa | 2022 |
Peripheral Delivery of Neural Precursor Cells Ameliorates Parkinson's Disease-Associated Pathology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Embryonic Stem Cells; | 2019 |
Activation of CB2R with AM1241 ameliorates neurodegeneration via the Xist/miR-133b-3p/Pitx3 axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cannabinoids; Disease Models, Animal; Dopamin | 2020 |
Bruceine D elevates Nrf2 activation to restrain Parkinson's disease in mice through suppressing oxidative stress and inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2020 |
Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Astrocytes; Behavior, Animal; Dopa | 2020 |
Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Gen | 2021 |
NLRP3 Inflammasome Inhibition Prevents α-Synuclein Pathology by Relieving Autophagy Dysfunction in Chronic MPTP-Treated NLRP3 Knockout Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autophagy; Corpus Striatum; | 2021 |
Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ascorbic Acid; Benzothiazoles; | 2017 |
Whole-Transcriptome Analysis of Mouse Models with MPTP-Induced Early Stages of Parkinson's Disease Reveals Stage-Specific Response of Transcriptome and a Possible Role of Myelin-Linked Genes in Neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cluster Analysis; Disease Models, Animal; Exo | 2018 |
Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gait; Hindlimb; Homeo | 2018 |
Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Line; Corpus Striatum; | 2018 |
Genetic suppression of collapsin response mediator protein 2 phosphorylation improves outcome in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2019 |
Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Astrocytes; Corpus St | 2019 |
miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antagomirs; Disease Models, Animal; Dopamine; | 2019 |
Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2014 |
Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; B | 2013 |
Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes | 2013 |
Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axonal Transport; Blotting, Western; Dopamine | 2013 |
Alterations in energy metabolism, neuroprotection and visual signal transduction in the retina of Parkinsonian, MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electron Transport; Electrophoresis, Gel, Two | 2013 |
Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin II; Angiotensin II Type 1 Receptor Blocker | 2014 |
PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cell Line, Tumor; Disease Models, | 2014 |
Tat-fused recombinant human SAG prevents dopaminergic neurodegeneration in a MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Line, Tumor; Dopaminergic Neu | 2014 |
PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Behavior, Animal; Cells, Cultured | 2015 |
Targeted toxicants to dopaminergic neuronal cell death.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Dise | 2015 |
Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2015 |
Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Caudate Nucleus; Conditioni | 2015 |
Preferential Heme Oxygenase-1 Activation in Striatal Astrocytes Antagonizes Dopaminergic Neuron Degeneration in MPTP-Intoxicated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Dopamine; Dopaminergic Neurons; E | 2016 |
Chronic and progressive Parkinson's disease MPTP model in adult and aged mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Catecholamines; Chronic D | 2016 |
Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Aquaporin 4; Astrocytes; Chron | 2016 |
Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2016 |
7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopaminergic Neurons; Flavo | 2016 |
The Essential Role of Drp1 and Its Regulation by S-Nitrosylation of Parkin in Dopaminergic Neurodegeneration: Implications for Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2016 |
FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Apoptos | 2016 |
Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Brain; Cell Count; Cholesterol; C | 2017 |
Early upregulation of 18-kDa translocator protein in response to acute neurodegenerative damage in TREM2-deficient mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Carrier Proteins; Disease Mode | 2017 |
Molecular imaging reveals a correlation between 2'-CH3-MPTP-induced neonatal neurotoxicity and dopaminergic neurodegeneration in adult transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Animals, Newborn; Brain; Disease Model | 2008 |
Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Brain; Chromatograph | 2008 |
GSTpi expression in MPTP-induced dopaminergic neurodegeneration of C57BL/6 mouse midbrain and striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Caspase 3; Corpus | 2009 |
Extranigral neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calpain; Cell Line; Dipeptides; Hu | 2008 |
Protective effect against Parkinson's disease-related insults through the activation of XBP1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcysteine; Animals; | 2009 |
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
MPTP intoxication in mice: a useful model of Leigh syndrome to study mitochondrial diseases in childhood.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Basal Ganglia Diseases; Diseas | 2009 |
Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Animals, Newborn; Cells | 2009 |
Macroautophagy of the GPR37 orphan receptor and Parkinson disease-associated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Gene Expression Regulation; Mice; | 2009 |
Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Corpus Striatum; Disease Mod | 2009 |
Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Aging; Animals; Axons; Cell Death; Dise | 2009 |
Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Biomarkers; Cytokines; Di | 2009 |
Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Immunohistochemistry; Inflammation; Macaca fa | 2009 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiograph | 2010 |
Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzamides; Brain; Disease Models, Animal; En | 2010 |
MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Avoidance Learning; Bra | 2009 |
Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Apoptos | 2010 |
Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2010 |
Exercise protects against MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytoprotection; Disease Models, Animal; Femal | 2010 |
Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cells, Cultured; Chronic Disease; Corp | 2010 |
Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalepsy; Cell Death; Dopamine; Genetic Ther | 2010 |
Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Behavior, Animal; Caspase 3; Cell | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cells, Cultured; Chromatography, | 2010 |
Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Brain; CD11b Antigen; Cell Count; Corp | 2010 |
Minor retinal degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Hallucinations; Haplorhini; Humans; | 2011 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Docosahexaenoic Acids | 2010 |
A neuroprotective role for angiogenin in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cell Line, Tumor; Cytoprotection; | 2011 |
Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Count; Cocu | 2011 |
The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Ileitis; Ileum; Immunity, Innate; I | 2011 |
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Brain Mapping; C | 2011 |
Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Analysis of Variance; Animals; bcl-2- | 2011 |
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid; | 2011 |
High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chemokine CCL2; Chemokine CCL3; Corpus Striat | 2012 |
Acupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Points; Acupuncture Therapy; Animals; Beha | 2011 |
Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibodies; Axons; Cells, Cultured; Corpus St | 2012 |
Experimental modeling of preclinical and clinical stages of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2011 |
Correlation between decreased motor activity and dopaminergic degeneration in the ventrolateral putamen in monkeys receiving repeated MPTP administrations: a positron emission tomography study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopaminergic Neurons; Macaca fascicularis; Ma | 2012 |
Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Dopaminergic Neurons; Gene Tran | 2012 |
Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apoptosis; Cell Count; Corpu | 2012 |
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Beha | 2012 |
Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-Associated Death Protein; Cell Death; Dis | 2012 |
Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antigens, CD; Capsaicin | 2012 |
Effects of age-related dopaminergic neuron loss in the substantia nigra on the circadian rhythms of locomotor activity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Circadian Rhythm; Dopamine Agents; Dop | 2012 |
Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Diseas | 2012 |
The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Calbindin 1; Calbindins; Cell Count; C | 2013 |
Gremlin is a novel VTA derived neuroprotective factor for dopamine neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Dopamin | 2013 |
Neural stem cells, scaffolds, and chaperones.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biocompatible Materials; Cell Survival; Dextr | 2002 |
Catecholaminergic neuronal degeneration in rainbow trout assessed by skin color change: a model system for identification of environmental risk factors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; Animals; Catecholamines; Do | 2002 |
Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Cell Count; Cell Death; Disease Models | 2003 |
Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Dopamine; Down-Regula | 2003 |
Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Coculture Techniques; Dopamine; Drug Synergis | 2003 |
Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Nucleus; Dopamine; Dopamine A | 2003 |
Injury and strain-dependent dopaminergic neuronal degeneration in the substantia nigra of mice after axotomy or MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axotomy; Cell Count; Cell Death; Dopamine; Do | 2003 |
MPP(+)-induced degeneration is potentiated by dicoumarol in cultures of the RCSN-3 dopaminergic cell line. Implications of neuromelanin in oxidative metabolism of dopamine neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Calpain; Cell De | 2003 |
TorsinA, the gene linked to early-onset dystonia, is upregulated by the dopaminergic toxin MPTP in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age of Onset; Animals; Animals, Newborn; Carrier Prote | 2004 |
Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Dopamine Agents; Dose-Respon | 2004 |
Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Calbindins; Corpus St | 2004 |
Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Blotting, Western; | 2004 |
Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Corpus Striatum; Dopamine; Dopami | 2004 |
Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apoptosis; Behavior, Animal; Dep | 2005 |
Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Stem; Cell Nucleus; Glutathione; Hydroq | 2005 |
Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain-Derived Neurotrop | 2005 |
Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caloric Restriction; Corpus Striatum; Disease | 2005 |
Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Carbolines; Caspase 3; Caspases; D | 2006 |
Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dise | 2005 |
Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Interleukin-1; Macaca fascicularis; | 2005 |
Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Plasma Membrane Tra | 2005 |
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Levodopa; Male; Mice; Mice, Inbred C57BL; Mic | 2005 |
The neurotoxin 2'-NH2-MPTP degenerates serotonin axons and evokes increases in hippocampal BDNF.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Axons; Biogenic Monoami | 2006 |
Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Coculture Techniques; Dinopr | 2006 |
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Blotting, Western; Disease Models, | 2006 |
Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Brain; Cell Death; Corpus | 2006 |
Doxycycline-regulated co-expression of GDNF and TH in PC12 cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Bacterial Agents; Dopamine; Doxycycline; | 2006 |
Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Automation; Behavio | 2006 |
Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Dopamine; Exploratory Beh | 2007 |
Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin-Converting Enzyme Inhibitors; Animals; Ant | 2006 |
Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Apoptotic Protease-Activating Fact | 2006 |
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Age Factors; Aging; Animals; Ani | 2007 |
Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Benzopyrans; Cor | 2006 |
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Biomarkers; Cerebral Co | 2006 |
MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amygdala; Animals; Axons; Corpus Striatum; Disease Mod | 2005 |
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Cell Survival; Cells, Cult | 2007 |
GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibodies; Corpus Striatum; Glial Cell Line- | 2007 |
Neuroprotection in Parkinson models varies with toxin administration protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, Nuclear; Axons; Benzothiazoles; Bio | 2006 |
Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Survival; Chemokines; Corpus Stri | 2007 |
Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Fluoresceins; Male; Mice; Mice, I | 2007 |
Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animal | 2007 |
Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Calorimetry, Indirect; Citr | 2007 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhala | 2007 |
Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclooxygenase 2; Disease Models, Animal; Dru | 2007 |
Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Disease Mo | 2007 |
Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine Plasma Membrane Tra | 2008 |
Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Benzhydryl Compounds; Biomarke | 2008 |
Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Analysis of Variance; Animals; Behavior, | 2008 |
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Dis | 2008 |
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Glial Cell Line-Derived Neurotrophi | 1995 |
MPTP-induced degeneration: interference with glutamatergic toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Dopamin | 1994 |
The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Arousal; Benzhydryl Compounds; B | 1993 |
Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1993 |
MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Blood-Brain Barrier; Ca | 1994 |
Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Calcium; Calcium Channels; Cell Death; | 1993 |
Immunological changes in the MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibody-Producing Cells; Cell Migration Inhi | 1993 |
Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain-Derived Neurotrophic Factor; Mac | 1995 |
Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Autoradiography; Bas | 1995 |
Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antihypertensive Agents; Axons; Dizocilpine M | 1997 |
The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 1996 |
Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calbindin 1; Calbindins; Dopamine; Dopamine A | 1996 |
Systemic administration of MPTP induces thalamic neuronal degeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dizocilpine Maleate; Dopamine Agents; Male; M | 1997 |
Kinetics of nigral degeneration in a chronic model of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Chronic Dis | 1997 |
Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Drug Administration Schedule | 1997 |
Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1998 |
Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 8-Hydroxy-2-(di-n-propyla | 1998 |
Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carbon Radioisotopes; Corpus Striatum; | 1998 |
Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaloids; Animals; Azocines; Benzenesulfonates; Dopam | 1998 |
CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calcium-Calmodulin-Dependent Prote | 1999 |
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Cell Death; Humans; Male; Nerve Degeneration; S | 1999 |
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Ani | 1999 |
Ultrastructural changes in substantia nigra and striatum observed on a mouse model of Parkinson's disease induced by MPTP administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Male; Mice; Mice, Inbred Str | 1999 |
Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; | 2000 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Dithiothr | 2000 |
Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Behavior, Animal; Bridged Bicy | 2000 |
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antigens, CD; Dihydroxyphenylalanine; | 2000 |
Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexa | 2000 |
Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Brain; Disease Models, Anima | 2001 |
cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Gene Expres | 2000 |
Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Progression; Dopamine; Dopamine Agent | 2001 |
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalase; Catechin; Dopamine; Dopamine Agents | 2001 |
Microtubule assembly is directly affected by MPP(+)in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cattle; Dose-Res | 2001 |
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antineoplastic A | 2002 |
Molecular basis of discrepancies in neurotoxic properties among 1-methyl-4-aryl-1,2,3,6-tetrahydropyridines.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Dopamine; Dopamine Agents; G | 1992 |
MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caudate Nucleus; | 1992 |
A lot of "excitement' about neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Alzheimer Disease; Animals; Dizocilpine Maleate | 1991 |
Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Brain; Brain Chemistry; Female | 1988 |
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholinesterase; Dop | 1988 |
Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57 BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Hydroxydopamines; Male; Mazindol; M | 1988 |
Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Mice; Mice, Inbred C57BL; Ne | 1988 |
GM1 ganglioside protects against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; G(M1) Ganglioside; Mice; Mic | 1988 |
[New clues to the etiology of Parkinson disease: parkinsonism induced by the neurotoxin MPTP].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Humans; Mice; Nerve Degenera | 1986 |
Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Male; Mazindol; Mi | 1986 |
Effects of the parkinsonism-inducing neurotoxin MPTP and its metabolite MPP+ on sympathetic adrenergic nerves in mouse iris and atrium.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adrenergic Fibers; Animal | 1986 |
Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Dopamine; Male; Metha | 1987 |
MPTP, impairment of motor performance and amine accumulation in Macaca fascicularis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Catecholamines; Dose-Response Relation | 1987 |
MPTP produces a mosaic-like pattern of terminal degeneration in the caudate nucleus of dog.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dogs; Male; Nerve Degenerati | 1987 |